Dale Porter
Cambridge, Massachusetts, United States
3K followers
500 connections
Activity
-
SCRIP magazine has just published an article on our innovation strategy in oncology, following an extensive interview with Francesco Hofmann, our…
SCRIP magazine has just published an article on our innovation strategy in oncology, following an extensive interview with Francesco Hofmann, our…
Liked by Dale Porter
-
🏃♀️Le 29 septembre prochain, nous courons solidaire à Saint-Cloud pour la 13ème édition de Imagine for Margo - Children without Cancer, Enfants…
🏃♀️Le 29 septembre prochain, nous courons solidaire à Saint-Cloud pour la 13ème édition de Imagine for Margo - Children without Cancer, Enfants…
Liked by Dale Porter
-
An Approved Brain-Penetrant mIDH1/2 Inhibitor with Stunning Efficacy in Glioma | https://lnkd.in/gSUAsgQy Vorasidenib (Voranigo®) is a…
An Approved Brain-Penetrant mIDH1/2 Inhibitor with Stunning Efficacy in Glioma | https://lnkd.in/gSUAsgQy Vorasidenib (Voranigo®) is a…
Liked by Dale Porter
Publications
-
Lipophilic Isosteres of a π-π Stacking Interaction: New Inhibitors of the Bcl-2-Bak Protein-Protein Interaction.
ACS medicinal chemistry letters
The discovery of new Bcl-2 protein-protein interaction antagonists is described. We replaced the northern fragment of ABT737 (π-π stacking interactions) with structurally simplified hydrophobic cage structures with much reduced conformational flexibility and rotational freedom. The binding mode of the compounds was elucidated by X-ray crystallography, and the compounds showed excellent oral bioavailability and clearance in rat PK studies.
-
The landscape of somatic copy-number alteration across human cancers
Nature
A powerful way to discover key genes with causal roles in oncogenesis is to identify genomic regions that undergo frequent alteration in human cancers. Here we present high-resolution analyses of somatic copy-number alterations (SCNAs) from 3,131 cancer specimens, belonging largely to 26 histological types. We identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene…
A powerful way to discover key genes with causal roles in oncogenesis is to identify genomic regions that undergo frequent alteration in human cancers. Here we present high-resolution analyses of somatic copy-number alterations (SCNAs) from 3,131 cancer specimens, belonging largely to 26 histological types. We identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene located within these regions. Several gene families are enriched among these regions of focal SCNA, including the BCL2 family of apoptosis regulators and the NF-kappaBeta pathway. We show that cancer cells containing amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival. Finally, we demonstrate that a large majority of SCNAs identified in individual cancer types are present in several cancer types.
More activity by Dale
-
We are pleased to welcome Dr. Daniel Erlanson to the Drug Hunter Scientific Advisory Board! Dr. Erlanson brings over 25 years of experience in the…
We are pleased to welcome Dr. Daniel Erlanson to the Drug Hunter Scientific Advisory Board! Dr. Erlanson brings over 25 years of experience in the…
Liked by Dale Porter
-
🤝 We’re excited to welcome Carlos Garcia-Echeverria, Ph.D., Katharina Kreymborg and Karen Lackey to our Therapeutic Innovation board to drive our…
🤝 We’re excited to welcome Carlos Garcia-Echeverria, Ph.D., Katharina Kreymborg and Karen Lackey to our Therapeutic Innovation board to drive our…
Liked by Dale Porter
-
Want to boost your productivity? Get outside! Walking meetings are a great way to improve creativity and free thinking, while also staying active. I…
Want to boost your productivity? Get outside! Walking meetings are a great way to improve creativity and free thinking, while also staying active. I…
Liked by Dale Porter
-
Looking forward to presenting at and participating to the popular “Rosenön meeting” organized by Apotekarsocieteten in the beautiful Swedish town of…
Looking forward to presenting at and participating to the popular “Rosenön meeting” organized by Apotekarsocieteten in the beautiful Swedish town of…
Liked by Dale Porter
-
Delighted to share the news that the U.S. FDA has accepted our New Drug Application for vimseltinib for priority review.
Delighted to share the news that the U.S. FDA has accepted our New Drug Application for vimseltinib for priority review.
Liked by Dale Porter
-
This year’s summer intern class brought fresh perspectives across translational medicine, public affairs, communications, biostatics, healthcare…
This year’s summer intern class brought fresh perspectives across translational medicine, public affairs, communications, biostatics, healthcare…
Liked by Dale Porter
-
It is a privilege to be among the nominees for the Boston Highlight category for the upcoming 2024 #BiotechWeekBoston Awards. This category…
It is a privilege to be among the nominees for the Boston Highlight category for the upcoming 2024 #BiotechWeekBoston Awards. This category…
Liked by Dale Porter
-
Last week Eli Lilly and Company opened its new genetic medicines-focused R&D center in Boston. I sat down with Daniel Skovronsky and Andrew Adams to…
Last week Eli Lilly and Company opened its new genetic medicines-focused R&D center in Boston. I sat down with Daniel Skovronsky and Andrew Adams to…
Liked by Dale Porter
-
La Jolla-based Avalon BioVentures' biotech startup Nerio Therapeutics has been acquired in a $1.3 billion deal by Boehringer Ingelheim. I spoke…
La Jolla-based Avalon BioVentures' biotech startup Nerio Therapeutics has been acquired in a $1.3 billion deal by Boehringer Ingelheim. I spoke…
Liked by Dale Porter
-
We recently celebrated the Yale Cancer Center Hematology-Medical Oncology Fellows Class of 2027 with a welcome reception, dinner, and introductions…
We recently celebrated the Yale Cancer Center Hematology-Medical Oncology Fellows Class of 2027 with a welcome reception, dinner, and introductions…
Liked by Dale Porter
-
Having recently retired from a 100k employee Fortune 500 company, where I absolutely loved to work, I am now spending more time with smaller…
Having recently retired from a 100k employee Fortune 500 company, where I absolutely loved to work, I am now spending more time with smaller…
Liked by Dale Porter
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Dale Porter in United States
-
Dale Porter
-
Dale Porter
Principal Owner - Defense Contractor
-
Dale Porter
-
Dale Porter
Dean of Workforce Development at Cochise College (Interim)
117 others named Dale Porter in United States are on LinkedIn
See others named Dale Porter